Fibrobiologics, INC S-1 registration statements

FibroBiologics, Inc. announces a public offering of common stock and warrants to raise capital and address ongoing Nasdaq listing compliance issues, including a recent 1-for-20 reverse stock split.

FibroBiologics, a clinical-stage biotech, filed an S-1 registration statement for the resale of up to 22.5 million common shares underlying warrants issued in recent private placements, with potential gross proceeds of $7.5 million to the company upon warrant exercise.

FibroBiologics has filed an amendment to its registration statement for the resale of up to 41,489,581 shares of common stock by YA II PN, LTD.

FibroBiologics' Chief Financial Officer, Mark Andersen, has resigned, with a transition agreement in place until November 15, 2024, while the company files an S-1 registration for a potential $25 million stock offering.

FibroBiologics has filed an S-1 registration statement for the resale of up to 16,022,644 shares of its common stock by GEM Global Yield LLC SCS, representing a significant portion of the company's public float.

FibroBiologics is seeking to raise up to $20 million through the sale of units, each comprising one share of common stock and one warrant.

FibroBiologics is launching a best-efforts offering of up to 1,801,801 units, each comprising a share of common stock and a warrant, to raise capital for research, development, and general corporate purposes.

FibroBiologics is seeking to raise up to $20 million through the sale of units, each comprising a share of common stock and a warrant.

FibroBiologics files an amendment to its S-1 registration statement to register the resale of approximately 1.5 million shares of common stock by GEM Global Yield LLC SCS and GEM Yield Bahamas Limited.

FibroBiologics files an amendment to its registration statement for the resale of common stock and warrants issued to GEM Global Yield LLC SCS and GEM Yield Bahamas Limited.

FibroBiologics, a clinical-stage cell therapy company, is registering the resale of 65,447 common shares to satisfy registration rights tied to a 2021 share purchase agreement, following its direct listing on the Nasdaq Global Market.

FibroBiologics updates its registration statement for a direct listing on the Nasdaq Global Market, anticipating trading to commence around January 31, 2024.

FibroBiologics updates its registration statement for a direct listing on the Nasdaq Global Market, planning for the resale of up to 4,806,226 shares of common stock by existing stockholders.

FibroBiologics, Inc. has engaged Maxim Group LLC as its financial advisor and investment banker to provide general financial advisory and investment banking services, including assistance with a potential direct listing or other go-public transactions.

FibroBiologics updates its registration statement for a direct listing on the Nasdaq Global Market, detailing the resale of common stock by existing stockholders.